Impact of tobacco smoking and alcohol consumption on the treatment efficacy among psoriasis patients: A study protocol
Psoriasis is a common skin disease. With an in-depth understanding of psoriasis, small-molecule drugs and biologics are developed and used in clinical practice, but some patients still cannot achieve a satisfactory therapeutic effect. Tobacco smoking and alcohol drinking are proven to be factors aff...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Publishing
2024-11-01
|
| Series: | Tobacco Induced Diseases |
| Subjects: | |
| Online Access: | https://www.tobaccoinduceddiseases.org/Impact-of-tobacco-smoking-and-alcohol-consumption-on-the-treatment-efficacy-among,195380,0,2.html |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Psoriasis is a common skin disease. With an in-depth understanding of psoriasis,
small-molecule drugs and biologics are developed and used in clinical practice,
but some patients still cannot achieve a satisfactory therapeutic effect. Tobacco
smoking and alcohol drinking are proven to be factors affecting psoriasis. Still,
evidence of the impact of tobacco smoking and alcohol consumption on the efficacy
of psoriasis treatment is limited. This study aims to understand the prevalence of
tobacco smoking and alcohol drinking among patients with psoriasis in Shanghai
and to examine the association between tobacco smoking as well as alcohol
drinking and the therapeutic effect in patients with psoriasis. We conducted a
longitudinal observational study and recruited at least 500 psoriasis patients at
Shanghai Skin Disease Hospital. In this study, patients with clinically diagnosed
psoriasis vulgaris, aged ≥18 years, both males and females, with informed consent
were recruited. However, patients with pregnancy, serious underlying disease
conditions, communication barriers, and violation of medication regulations were
excluded. Patients with psoriasis in this study receive a physical examination and
case record form interview. The primary outcome indicator is the proportion
of patients with PASI 75 achievement at Week 8. In this study, we use SAS 9.2
software to analyze the data. This study has been reviewed and approved by
the Institutional Ethics Review Committee of Shanghai Skin Disease Hospital
in 2021 (NO. 2021-44). It has been registered in the Chinese Clinical Trial
Registry (ChiCTR2200066403). Patient recruitment began in January 2021 and is
proposed to be finished in December 2024. The findings in this study will provide
evidence of how tobacco smoking and alcohol drinking impact the treatment
efficacy among patients with psoriasis. Therefore, the implementation of tobacco
control and alcohol abstinence benefit the improvement of treatment responses. |
|---|---|
| ISSN: | 1617-9625 |